Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D, Inzucchi SE, Koudstaal S, Ofstad AP, Schrage B, Vedin O, Wanner C, Zannad F, Zwiener I, Butler J. Savarese G, et al. Among authors: zwiener i. J Card Fail. 2021 Aug;27(8):888-895. doi: 10.1016/j.cardfail.2021.05.012. J Card Fail. 2021. PMID: 34364665 Free article. Clinical Trial.
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Butler J, et al. Among authors: zwiener i. Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5. Circ Heart Fail. 2019. PMID: 31163986
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S, Sharma A, Zinman B, Ofstad AP, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George JT, Inzucchi SE, Butler J, Mazer CD. Verma S, et al. Among authors: zwiener i. Diabetes Obes Metab. 2020 Jul;22(7):1141-1150. doi: 10.1111/dom.14015. Epub 2020 Mar 29. Diabetes Obes Metab. 2020. PMID: 32227432 Free PMC article. Clinical Trial.
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Verma S, Ji Q, Bhatt DL, Mazer CD, Al-Omran M, Inzucchi SE, Wanner C, Ofstad AP, Zwiener I, George JT, Zinman B, Fitchett D. Verma S, et al. Among authors: zwiener i. Diabetes Obes Metab. 2020 Jul;22(7):1207-1214. doi: 10.1111/dom.13991. Epub 2020 Mar 28. Diabetes Obes Metab. 2020. PMID: 32030863 Free PMC article. Clinical Trial.
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Verma S, Mazer CD, Inzucchi SE, Wanner C, Ofstad AP, Johansen OE, Zwiener I, George JT, Butler J, Zinman B. Verma S, et al. Among authors: zwiener i. Diabetes Obes Metab. 2021 May;23(5):1173-1181. doi: 10.1111/dom.14326. Epub 2021 Feb 24. Diabetes Obes Metab. 2021. PMID: 33502090 Free PMC article.
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Ferreira JP, Kraus BJ, Zwiener I, Lauer S, Zinman B, Fitchett DH, Koitka-Weber A, George JT, Ofstad AP, Wanner C, Zannad F. Ferreira JP, et al. Among authors: zwiener i. J Am Heart Assoc. 2021 Apr 6;10(7):e020053. doi: 10.1161/JAHA.120.020053. Epub 2021 Mar 23. J Am Heart Assoc. 2021. PMID: 33754809 Free PMC article. Clinical Trial.
70 results